Skip to main content

Nipent Side Effects

Generic name: pentostatin

Medically reviewed by Drugs.com. Last updated on Feb 12, 2024.

Note: This document provides detailed information about Nipent Side Effects associated with pentostatin. Some dosage forms listed on this page may not apply specifically to the brand name Nipent.

Applies to pentostatin: intravenous powder for solution.

Important warnings This medicine can cause some serious health issues

Intravenous route (powder for solution)

Pentostatin should be administered under the supervision of a physician qualified and experienced in the use of cancer chemotherapeutic agents.

The use of doses higher than those specified is not recommended.

Dose-limiting severe renal, liver, pulmonary, and CNS toxicities occurred in Phase 1 studies that used pentostatin at higher doses (20 to 50 mg/m(2) in divided doses over 5 days) than recommended.

In a clinical investigation in patients with refractory chronic lymphocytic leukemia using pentostatin at the recommended dose in combination with fludarabine phosphate, 4 of 6 patients entered in the study had severe or fatal pulmonary toxicity.

The use of pentostatin in combination with fludarabine phosphate is not recommended.

Common side effects of Nipent

Some side effects of pentostatin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • diarrhea
  • headache
  • loss of appetite
  • muscle pain
  • nausea and vomiting
  • skin rash

Less common

  • back pain
  • bloating or gas
  • constipation
  • dry skin
  • general feeling of discomfort or illness
  • itching
  • joint pain
  • weakness
  • weight loss

Serious side effects of Nipent

Along with its needed effects, pentostatin may cause some unwanted effects. Some side effects will have signs or symptoms that you can see or feel. Your doctor may watch for others by doing certain tests.

Also, because of the way these medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer. Discuss these possible effects with your doctor.

Check with your doctor immediately if any of the following side effects occur while taking pentostatin:

More common

  • cough or hoarseness
  • fever or chills
  • lower back or side pain
  • pain
  • painful or difficult urination
  • skin rash or itching (sudden)
  • unusual tiredness or weakness

Less common

  • anxiety or nervousness
  • black, tarry stools
  • blood in the urine or stools
  • changes in vision
  • chest pain
  • confusion
  • cramps in lower legs
  • mental depression
  • nosebleed
  • numbness or tingling of the hands or feet
  • pinpoint red spots on the skin
  • shortness of breath
  • sleepiness
  • sore, red eyes
  • sores in the mouth or on the lips
  • stomach pain
  • swelling of the feet or lower legs
  • trouble with sleeping
  • unusual bleeding or bruising

Serious side effects of Nipent

Along with its needed effects, pentostatin (the active ingredient contained in Nipent) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

For healthcare professionals

Applies to pentostatin: intravenous powder for injection.

Hematologic

Gastrointestinal

Dermatologic

Hepatic

Genitourinary

Respiratory

Nervous system

Cardiovascular

Hypersensitivity

Ocular

Musculoskeletal

Metabolic

Immunologic

Psychiatric

Oncologic

Other

Renal

References

1. Kraut EH, Neff JC, Bouroncle BA, Gochnour D, Grever MR (1990) "Immunosuppressive effects of pentostatin." J Clin Oncol, 8, p. 848-55

2. Cheson BD (1995) "Infectious and immunosuppressive complications of purine analog therapy." J Clin Oncol, 13, p. 2431-48

3. (2001) "Product Information. Nipent (pentostatin)." Hospira Inc

4. Sorensen JM, Chun HG, Vena D, Fallavollita A, Cheson BD (1991) "PENTOSTATIN (DCF) THERAPY FOR HAIRY CELL LEUKEMIA (HCL): UPDATE OF A GROUP C PROTOCOL OF 208 PATIENTS (PTS) WHO HAVE FAILED INTERFERON ALPHA (IFNA) (MEETING ABSTRACT)." Proc Annu Meet Am Soc Clin Oncol, 10, a7871991

5. Cassileth PA, Cheuvart B, Spiers AS, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ (1991) "Pentostatin induces durable remissions in hairy cell leukemia." J Clin Oncol, 9, p. 243-6

6. Grem JL, King SA, Chun HG, Grever MR (1991) "Cardiac complications observed in elderly patients following 2'- deoxycoformycin therapy." Am J Hematol, 38, p. 245-7

7. Bruno JJ, Canada TW (2007) "Possible pentostatin-induced symptomatic hyponatremia." Pharmacotherapy, 27, p. 164-9

Further information

Nipent side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.